Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1565 articles by Jacob Bell
-
Biogen: Don’t expect any big acquisitions this year
April 24, 2024 -
Biogen to invest more in launch of Alzheimer’s drug Leqembi
April 24, 2024 -
Neurocrine scores surprise win with depression drug
April 23, 2024 -
Sage’s cognition drug fails in Parkinson’s study
April 17, 2024 -
Intra-Cellular builds case for depression drug with late-stage trial win
April 16, 2024 -
Neumora’s schizophrenia drug hit with clinical hold
April 15, 2024 -
Roche, Adaptimmune part ways on cell therapy research
April 12, 2024 -
PureTech launches Seaport, hoping to create Karuna 2.0
April 9, 2024 -
Psychiatry drugs finally have pharma’s attention. Can they keep it?
April 8, 2024 -
Amylyx to pull ALS drug from market in rare move
April 4, 2024 -
Paragon’s hub-and-spoke biotech model yields another reverse merger
April 3, 2024 -
Acorda files for bankruptcy, reveals asset sale plan
April 2, 2024 -
European study finds popular ALS drug ineffective
March 27, 2024 -
Axsome drug succeeds in narcolepsy symptoms trial
March 25, 2024 -
Acelyrin eye drug heads to late-stage testing after trial win
March 20, 2024 -
Engrail’s precision psychiatry drugs get more buy in from venture investors
March 19, 2024 -
Bristol Myers cell therapy wins first-of-its-kind approval
March 15, 2024 -
After surprise trial failure, ALS doctors brace for one less treatment option
March 12, 2024 -
Amylyx CEOs look for a path forward following major setback
March 11, 2024 -
Amylyx ALS drug fails crucial study, putting company’s future in doubt
March 8, 2024 -
NodThera says inflammation drug has positive effect in Parkinson’s
March 7, 2024 -
Gilead bets on ‘trispecifics’ in latest cancer drug deal
March 6, 2024 -
Bayer isn’t splitting up, for now
March 5, 2024 -
Cure Ventures backs a cell therapy startup targeting Parkinson’s
Feb. 29, 2024 -
Incannex says psilocybin therapy lowered anxiety in small study
Feb. 28, 2024